Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026

Sarepta Therapeutics, Inc. faces revenue decline, trial setbacks, and FDA decisions. Click for SRPT risks, outlook, and if ...

Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months– – Combination ...

Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Matthew ...
Frontiers

In Situ Biomarkers: Advancing Precision Medicine in Solid Tumours

The field of oncology has been profoundly impacted by malignant solid tumours, representing a significant challenge in healthcare. While strides have been ...

Point-of-Care Molecular Diagnostics Market Surges to USD 15.2 Billion by 2033, Propelled by 10.2% CAGR - Verified Market Reports®

The Point-of-Care Molecular Diagnostics Market is experiencing robust expansion driven by rising demand for rapid, accurate, ...
NAI500

Malaco Mountain assays point to copper-REE potential

New assays from the Malaco Mountain copper-gold-REE showing in Labrador Trough reveal high copper and gold grades, with potential for a polymetallic system, pointing to a promising new copper ...